EUVIMEDEUVIMED entdecken
Crossref

Single-cell transcriptome analysis reveals onco-fetal reprogramming with implications for drug resistance and clinical outcome

Yongle Xu, Shaoyi Chen, Zhenglin Lu, Yuqi Fan, Zhaoxin Liu, Wenhui Liu, Shiqian Zhang, Weijian Lu, Jianing Li, Changbo Yang, Gengdong Chen, Jingyi Shi und 8 weitere

Genome Research · 09.10.2026

DOI: 10.1101/gr.281292.125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genome Research, online erschienen am 09.10.2026. Verfasst von Yongle Xu und 19 weiteren Autor:innen. Beteiligte Einrichtung: College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150081, China. Gefördert von: National Science and Technology, National Natural Science Foundation of China, Natural Science Foundation of Heilongjiang Province.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Onco-fetal (OF) reprogramming of the tumor ecosystem induces fetal-like characteristics, leading to tumor growth and malignant progression. Here, we develop a robust computational pipeline to systematically identify OF cells, using single-cell transcriptomic data from corresponding fetal and tumor tissues across multiple cancer types. OF cells are consistently detected across diverse malignancies and exhibit pronounced stem-like properties. Core transcription factors involved in OF reprogramming are identified, including PTMA , ATF5 , TCF4 , and FOS , whose coordinated activities may promote tumor progression. Strategically positioned OF cells orchestrate tumor microenvironment cross talk, specifically impairing B cell function. OF cells are further verified in additional cancers, and we find that high OF cell abundance contributes to enhanced drug resistance and cancer recurrence. Critically, pancancer analyses establish that OF cell markers universally portend adverse prognoses. Overall, our study uncovers a clinically consequential cancer cell subpopulation and highlights its potential as a target for precision oncology.

Autor:innen und Institutionen

  • College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150081, China.
  • Thoracic Oncology Institute, Peking University People's Hospital, Beijing 100044, China.
  • Department of Thoracic Surgery, Peking University People's Hospital, Beijing 100044, China.
  • Research Unit of Intelligence Diagnosis and Treatment in Early Non-Small Cell Lung Cancer, Chinese Academy of Medical Sciences, 2021RU002, Peking University People's Hospital, Beijing 100044, China.
  • Institute of Advanced Clinical Medicine, Peking University, Beijing 100191, China.
  • Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, China.

Förderung

  • National Science and Technology
  • National Natural Science Foundation of China
  • Natural Science Foundation of Heilongjiang Province
  • Beijing Nova Program
  • Postdoctoral Scientific Research Developmental Fund of Heilongjiang Province

Zitieren

APA

Xu, Y., Chen, S., Lu, Z., Fan, Y., Liu, Z., Liu, W., Zhang, S., Lu, W., Li, J., Yang, C., Chen, G., Shi, J., Ding, N., Liu, S., Sun, X., Jiang, Q., Zhi, H., Sun, H., Qiu, M., & Shao, T. (2026). Single-cell transcriptome analysis reveals onco-fetal reprogramming with implications for drug resistance and clinical outcome. Genome Research. https://doi.org/10.1101/gr.281292.125

Vancouver

Xu Y, Chen S, Lu Z, Fan Y, Liu Z, Liu W, et al. Single-cell transcriptome analysis reveals onco-fetal reprogramming with implications for drug resistance and clinical outcome. Genome Research. 2026. doi:10.1101/gr.281292.125

BibTeX
@article{Xu2026,
  author = {Xu, Yongle and Chen, Shaoyi and Lu, Zhenglin and Fan, Yuqi and Liu, Zhaoxin and Liu, Wenhui and Zhang, Shiqian and Lu, Weijian and Li, Jianing and Yang, Changbo and Chen, Gengdong and Shi, Jingyi and Ding, Na and Liu, Shanshan and Sun, Xilin and Jiang, Qinghua and Zhi, Hui and Sun, Haoxiu and Qiu, Mantang and Shao, Tingting},
  title = {Single-cell transcriptome analysis reveals onco-fetal reprogramming with implications for drug resistance and clinical outcome},
  journal = {Genome Research},
  year = {2026},
  doi = {10.1101/gr.281292.125}
}
Kostenlos starten →